Blocking trans interaction between DSG2 and Siglec‐9 significantly enhances macrophage phagocytosis of melanoma cells, presenting sialylated DSG2 as a potential target in cancer immunotherapy. This evidence concerns the gene SIGLEC9 and melanoma.